- Affiliate Professor, Global Health
- Vice President, HIV Franchise Head, Gilead Sciences
Ninth and Jefferson Building 12th Floor
908 Jefferson Street
Seattle, WA 98104
Select from the following:
Dr. Baeten is Professor of Global Health, Medicine, and Epidemiology at the University of Washington. His research focuses on the prevention of HIV and other sexually transmitted diseases, including clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV transmission, work at the interface of HIV prevention and reproductive health, and behavioral, translational, and implementation science research aimed at optimizing prevention delivery. He led the Partners PrEP Study and MTN-020/ASPIRE, randomized clinical trials that demonstrated the efficacy of oral tenofovir-based pre-exposure prophylaxis (PrEP) and the dapivirine vaginal ring for protection against HIV acquisition; he also was part of the leadership of the ECHO Study, which examined HIV risk related to hormonal contraceptive use in a randomized trial. He is Co-Principal Investigator of the NIH-funded Microbicides Trials Network.
- MD (University of Washington)
- PhD (University of Washington)
- BA (Washington University)
- HIV Transmission
- STDs (other than HIV)
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus N, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker L-G, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Pather A, Naidoo L, Husnik M, Richardson BA, Parikh UM, Mellors JW, Marzinke MA, Hendrix CW, van der Straten A, Ramjee G, Chirenje ZM, Nakabiito C, Taha TE, Jones J, Mayo A, Scheckter R, Berthiaume J, Livant E, Jacobson C, Ndase P, White R, Patterson K, Germuga D, Galaska B, Bunge K, Singh D, Szydlo DW, Montgomery ET, Mensch BS, Torjesen K, Grossman CI, Chakhtoura N, Nel A, Rosenberg Z, McGowan I, Hillier S; MTN-020/ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121-2132.
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: A randomised, open-label clinical trial. Lancet. 2019;394:303-13.